Comparison between Crystal Crop Protection IPO and Symbiotec Pharmalab IPO.
Crystal Crop Protection IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Symbiotec Pharmalab IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Crystal Crop Protection IPO is up to ₹0.00 Cr whereas the issue size of the Symbiotec Pharmalab IPO is up to ₹2,180.00 Cr. The final issue price of Crystal Crop Protection IPO is and of Symbiotec Pharmalab IPO is .
| Crystal Crop Protection IPO | Symbiotec Pharmalab IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹2 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹600.00 Cr | up to ₹150.00 Cr |
| OFS Issue Size | 74,05,387 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹2,030.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹2,180.00 Cr |
Crystal Crop Protection IPO opens on , while Symbiotec Pharmalab IPO opens on . The closing date of Crystal Crop Protection IPO and Symbiotec Pharmalab IPO is , and , respectively.
Crystal Crop Protection IPO P/E ratio is , as compared to Symbiotec Pharmalab IPO P/E ratio of .
| Crystal Crop Protection IPO | Symbiotec Pharmalab IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Crystal Crop Protection Ltd.'s revenue increased by 20% and profit after tax (PAT) rose by 36% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Symbiotec Pharmalab Ltd.'s revenue increased by 5% and profit after tax (PAT) dropped by 3% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 86.69 | 34.47 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 8.31% | 12.66% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 16.43% | 11.80% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.65 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 7.46% | 11.79% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Crystal Crop Protection IPO Retail Individual Investors (RII) are offered 0 shares while in Symbiotec Pharmalab IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Crystal Crop Protection IPO and 0 shares in Symbiotec Pharmalab IPO.
| Crystal Crop Protection IPO | Symbiotec Pharmalab IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Crystal Crop Protection IPO subscribed in total, whereas Symbiotec Pharmalab IPO subscribed .
